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Employers have begun to offer voluntary workplace genomic testing (wGT) as part of
employee wellness benefit programs, but few empirical studies have examined the
ethical, legal, and social implications (ELSI) of wGT. To better understand employee
perspectives on wGT, employees were surveyed at a large biomedical research
institution. Survey respondents were presented with three hypothetical scenarios for
accessing health-related genomic testing: via (1) their doctor; (2) their workplace;
and 3) a commercial direct-to-consumer (DTC) genetic testing company. Overall, 594
employees (28%) responded to the survey. Respondents indicated a preference for
genomic testing in the workplace setting (70%; 95% CI 66–74%), followed by doctor’s
office (54%; 95% CI 50–58%), and DTC testing (20%; 95% CI 17–24%). Prior to
participating in wGT, respondents wanted to know about confidentiality of test results
(79%), existence of relevant laws and policies (70%), and privacy protection (64%).
Across scenarios, 92% of respondents preferred to view the test results with a genetic
counselor. These preliminary results suggest that many employees are interested and
even prefer genetic testing in the workplace and would prefer testing with support from
genetic health professionals. Confirmation in more diverse employer settings will be
needed to generalize such findings.
Keywords: workplace genomic testing, workplace wellness, employees, ELSI, genetic health professionals
INTRODUCTION
Voluntary workplace genomic testing (wGT) in the context of wellness programs is a growing access
point for genetic screening for disease risk (Singer, 2018). A 2017 Wamberg Genomic Consumer
Survey of 536 U.S. consumers with employer-sponsored health insurance reported that 65% of
employees would be interested in genetic testing if their employers offered easy and affordable
access with strict privacy and data ownership, allowing test result access only to the employee and
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their doctor1. wGT has the potential to lower overall healthcare
costs and improve health outcomes by encouraging employees to
become more vigilant about disease risks, make lifestyle changes
to manage these risks, and seek care before symptoms develop.
Thus, wGT as part of wellness programs might be able to inform
strategies to mitigate disease risks. However, whether wGT truly
influences behavior change and offers long-term benefits remains
an open question (Hollands et al., 2016; Burke et al., 2019; Yanes
et al., 2019). Additionally, existing studies on wellness programs
that report minimal benefits do not account for wGT, which is an
emerging area (Lieberman, 2019; Song and Baicker, 2019).
Genetic screening in the workplace and the potential
implementation of wGT as part of routine preventive medicine
was envisioned as early as the 1980s (Dabney, 1981). Although
wGT can inform employees of their genetic risk for certain
treatable diseases, it also raises concerns about genetic privacy
and workplace discrimination. There is also a recognition
that the acquisition and use of genetic data in workplace
settings might cause emotional distress and other psychosocial
harms (MacDonald and Williams-Jones, 2002). Furthermore,
the complex web of state and federal laws that regulate
medical information privacy and employer-provided group
health insurance coverage do not comprehensively ensure
protections against inappropriate use or misuse of wGT by third
parties, such as law enforcement or insurance companies (Annas,
2001; Drabiak, 2017; Hudson and Pollitz, 2017; Golinghorst and
Prince, 2020). Such uncertainty and legal concerns add to the
more direct concerns about how personal genomic data might
be used in the workplace setting (Lappé, 1983; Van Damme and
Casteleyn, 1998).
A better understanding of current factors affecting employee
decision-making regarding participation in wGT will help inform
research activities, education initiatives and policy development.
This study reports on a survey of employees of a large, U.S.
based, self-insured biomedical research institution with over
2,000 employees. Respondents were presented with hypothetical
scenarios for accessing health-related genomic testing for
screening purposes, then asked questions designed to: (a)
ascertain interest in wGT compared to other access points for
genetic testing, (b) assess employees’ perceived test concerns and
benefits, and (c) determine sociodemographic, psychological, and
situational correlates of test intentions.
MATERIALS AND METHODS
Study Population
Participants were drawn from a convenience sample of
employees of The Jackson Laboratory (JAX), a large biomedical
research institution with 2,090 employees headquartered in
Bar Harbor, ME with additional facilities in Sacramento,
California, and Farmington, Connecticut. The study was




study participation would have no negative consequences to
respondents’ employment at JAX. Participants were not offered
any inducement or incentive to participate in the study. The final
version of the survey was reviewed by institutional regulatory
and information security teams to ensure that study participation
would not be perceived by employees as offering actual genomic
testing and that employees’ privacy would be protected. The study
was approved by JAX Institutional Review Board (IRB).
Survey Development and Administration
An interdisciplinary team with expertise in legal and ethical
issues of genetic testing, psychosocial outcomes, and clinical
genetics developed a survey that included: (1) eighteen closed-
ended questions; (2) one open-ended question; and (3) six
demographic questions. Pilot testing with 8 JAX employees
and health professionals helped improve clarity of survey
items. Three hypothetical scenarios for accessing voluntary
health-related genomic testing were presented, including testing
through: (1) the participant’s doctor’s office; (2) an unspecified
workplace (wGT); and (3) the participant’s engagement in direct-
to-consumer (DTC) genetic testing. The scenarios included
descriptions of variable factors related to genomic testing
including cost, insurance implications, and sharing of test results.
These variable factors were included to most closely reflect the
current state of genetic screening across the three scenarios.
Notably, genetic test results are most likely to go into medical
records when testing occurs at a doctor’s office and direct-to-
consumer testing is most likely to incur out of pocket expenses
for an individual. Also, the hypothetical scenarios specifically
mentioned the types of conditions that would be tested and
did not include nutrition, fitness, or ancestry with an intention
to promote health risk reduction relevant to all participants
including those not taking any medications. A description of the
testing was provided in the survey prior to the questions (see
Supplementary Table S5). The complete survey is available in the
online supplement (see Supplementary Table S1).
The survey was administered online following an email
invitation in August 2018 (August 7–30) and was open to all JAX
employees. Beyond the initial email, recruitment efforts included
the following: (1) 1 week before the survey administration, paper
handouts were displayed at designated sites on all three campuses
along with a rolling display on wall-mounted video monitors
in high-traffic common spaces throughout each campus; (2)
a detailed description of the purpose of the study, types of
questions, safeguards to protect employees’ privacy, contact
information of the study team, and a set of Frequently Asked
Questions were posted on the JAX internal website; and (3)
reminder posts added to this website one and 3 weeks after
emailing the survey link. These reminder posts were again
supplemented by rolling announcements on video monitors in
high-traffic common spaces on each JAX campus. The survey
responses were compiled using QualtricsXM (August 2018,
Provo, Utah, United States).
Survey Measures
Sociodemographic characteristics collected by the survey
included self-reported sex, age, years employed at JAX, highest
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education level completed, ethnicity, and race based on U.S.
Census categories and examples from the National Institutes of
Health (NIH). Additional information was collected regarding
prior experience or interest in genomic testing; personal or
family member history with genomic testing; the primary
reason for seeking testing; and overall interest in genomic
testing. Participants selected their level of agreement with a
list of perceived benefits, risks, and limitations of genomic
testing in the context of the three different scenarios using
a 5-point Likert scale (1 = Strongly Disagree to 5 = Strongly
Agree) (Table 3). Participants also had a choice to select
“unsure” for each of the perceived benefits or concerns; for
analyses these responses were combined with the neither
agree/disagree response category. Prior research (Lerman
et al., 1996) on predictive testing for other disorders was
referenced to determine the risks and benefits selections available
to participants.
Specific to the wGT scenario, participants were asked about
questions that they would like answered prior to testing.
Examples of such questions included those about: (a) impact on
health, privacy and confidentiality; and (b) an opportunity to
discuss wGT with a genetic counselor. Preferences for receiving
results and factors influencing comfort or confidence with
wGT were also assessed. A single open-ended question was
included to elicit any additional thoughts on wGT that were not
covered in the survey.
Data Analysis
Descriptive statistics characterized participants in terms of their
sociodemographics, predictive testing intentions, and concerns
and perceived test benefits and concerns. Generalizability of
the responses to the general employee population at JAX
was assessed based on the available aggregate demographic
information of the employees at JAX. A perceived test benefit
score was derived by summing responses to four factors for
pursuing testing. Similarly, a perceived test concern score was
derived by summing responses to four factors for declining
testing (see Table 3). Cronbach’s alpha test was used to
evaluate the internal consistency of these summed scales.
Logistic regression was used to determine whether there were
associations between the test scenario and a positive response
(probably or definitely yes) to whether the respondent would
engage in genomic testing. Logistic regression was also used
to test for associations between respondent characteristics and
positive response (probably or definitely yes) to engaging in
genetic testing in the three scenarios. Odds ratios (OR) and
95% confidence intervals (CI) are presented. P-values < 0.05
were considered statistically significant. Statistical analyses
were conducted using SAS 9.4 (SAS Institute Inc., North
Carolina, United States).
Free text responses to the question on factors influencing
decision making for wGT were grouped into themes that were
selected inductively based on an initial review of responses and
refined through review by the broader study team. Themes were
then applied to individual responses in an Excel spreadsheet. This
approach was felt to be reasonable given that responses were
generally brief and focused.
RESULTS
Respondent Characteristics
Twenty eight percent (594/2,090) of all JAX employees (at the
time of survey administration) consented to participate in the
study of which 61% were female, 63% were older than 35, and
88% were White. Four percent (N = 20) of respondents preferred
not to reveal their gender. Table 1 summarizes the respondents’
sociodemographic characteristics: sex, age, years employed at
JAX, level of education completed, race, and ethnicity. In general,
the demographic characteristics of respondents were similar to
the overall employee population at JAX in age, sex, and race.
Prior Experiences and Interest in
Genomic Testing
Twenty two percent (130/593) of respondents reported that they
had taken a genomic test in the past. Ancestry testing (42%)
was the primary testing experience, followed by carrier testing
TABLE 1 | Demographics of the respondents.
Sociodemographic characteristics All respondents N (%) N = 594
Sex (N = 496)a
Female 290(60.9)
Male 186(39.1)





56 and above 65(13.3)
Years at JAX: (N = 493)





More than 20 years 51(10.3)
Education: (N = 494)
High School or GED 25(5.1)
Some college/associate degree 109(22.1)
Bachelor’s degree 176(35.6)
Master’s degree 87(17.6)
Professional school/doctoral degree 97(19.6)
Race: (N = 455)a
American Indian or Alaskan Native 5(1.1)
Asian 25(5.5)
Black or African American 4(0.9)
Native Hawaiian or other Pacific Islander 1(0.2)
White 399(87.7)
More than one race 21(4.6)
Ethnicity: (N = 464)a
Hispanic 27(5.8)
Non-hispanic 437(94.2)
aPrefer not to answer excluded and counted as missing.
Frontiers in Genetics | www.frontiersin.org 3 March 2021 | Volume 12 | Article 643304
fgene-12-643304 March 11, 2021 Time: 19:34 # 4
Sanghavi et al. Employees and Voluntary Workplace Genomic Testing
(16%), and predictive testing (11%), and prenatal testing (8%).
Twenty-one percent of respondents reported that their family
members had taken a genomic test in the past, while 13% were
unsure. Respondents indicated that their family member(s) had
sought ancestry testing (52%), health-related diagnostic testing
(13%), predictive testing (10%), or prenatal testing (10%).
Perceived Benefits, Limitations, and
Risks of Genetic Testing
Respondents were more likely to endorse test benefits than risks
or concerns for each scenario (Table 2). Early diagnosis/detection
had the highest number of respondents who agreed or strongly
agreed that it was a benefit (≥85%) across the 3 test scenarios.
Privacy/confidentiality had the highest number of respondents
who agreed or strongly agreed that it was a concern (≥70%).
Respondents were unsure whether potential work absenteeism
due to follow-up care was a concern in wGT (4%), doctor’s
office (4%), and DTC (6%) respectively. Regarding the perceived
benefit vs. risk or concern of wGT, 80% of respondents agreed
or strongly agreed with at least one listed perceived benefit to
wGT while 71% agreed or strongly agreed with at least one
concern raised by wGT.
Thirty four percent of respondents preferred to learn about
privacy and confidentiality safeguards followed by relevant laws
and policies (∼30%) prior to taking the test. Perceptions of
test benefits and risks are summarized in Table 3. Cronbach’s
alpha was 0.91, 0.90, and 0.92 for wGT, doctor’s office, and DTC
scenarios respectively for the benefits subscale. For the risks or
concerns subscale, Cronbach’s alpha was 0.77, 0.63, and 0.72
respectively. This signifies the overall reliability of the scale items
on perceived test benefits and risks or concerns. The percentage
of respondents indicating agreement with the perceived benefit
was lowest for the commercially available testing scenario for
each of the four perceived benefits (p ≤ 0.0001) (see Table 2).
However, the percent of agreement was high for three scenarios,
indicating an overall endorsement of perceived benefits across all
three scenarios. Fewer respondents were concerned about privacy
and confidentiality concerns and data use by an outside group
for the employer-based scenario (p < 0.0001). There were no
significant differences across groups for perceived concerns of
misunderstanding of test or work absence.
Respondents’ Attitudes Toward wGT
Respondents were likely or highly likely to opt for genomic
testing most commonly in the workplace setting (70%, 359/512,
95% CI 66–74%), followed by doctor’s office (54%, 286/529, 95%
CI 50–58%), and DTC testing (20%, 103/506, 95% CI 17–24%).
About 43% of respondents reported being most comfortable with
the workplace among the three scenarios for genomic testing,
followed by doctor’s office (25%), and DTC setting (9%). About
10% of respondents were uncomfortable with all three scenarios,
while 9% were comfortable with all three scenarios. About 4%
of respondents were unsure about their comfort with any of the
three scenarios. Respondents had increased odds of being likely
(probably or definitely) to take wGT (OR 1.99, 95% CI 1.63–2.43,
p < 0.0001) and reduced odds to use commercially available tests
(OR 0.22, 95% CI 0.17–0.28, p < 0.0001) compared to taking the
test in the doctor’s office. A summary of test preferences in the
three hypothetical scenarios appears in Table 3. In our cohort,
respondents with an associate degree or less had an odds ratio of
3.37 for interest in wGT as compared to those with a Doctor of
Philosophy (Ph.D) or Doctor of Medicine (MD). This trend was
seen in intermediate levels of education: Bachelor’s degree (OR
2.85) and Master’s degree (OR 1.15).
Factors Affecting Preference for wGT
Twenty percent of respondents indicated that there were other
factors that would make them more comfortable or confident
about taking wGT, while 15% of respondents indicated that
there might be some such factors. Across the free text responses
(159 comments), the most common broad categories of factors
were: (1) data access, ownership, and security, privacy and
TABLE 2 | Perceived test benefits, risks and concerns.
Test scenario
Employer based (% agree) Doctor’s office (% agree) Commercially available (% agree) p-value
Perceived benefit
Early diagnosis/detection 459/511 (90%) 485/529 (92%) 427/503 (85%) < 0.0001
Timely medical intervention 432/509 (85%) 460/529 (87%) 398/502 (79%) < 0.0001
Motivation for lifestyle change 440/510 (86%) 455/529 (86%) 402/501 (80%) 0.0001
Health risk info for children 411/511 (80%) 436/529 (82%) 370/502 (74%) < 0.0001
Perceived risk/concern
Privacy/confidentiality 360/510 (71%) 421/528 (80%) 392/504 (78%) < 0.0001
Date use by outside group 331/509 (65%) 390/527 (74%) 384/503 (76%) < 0.0001
Misunderstanding of test 264/510 (52%) 285/529 (54%) 270/504 (54%) 0.39
Work absence 179/510 (35%) 172/528 (33%) 158/503 (31%) 0.10
The frequencies and percentages in each row are based on those who responded “Agree” or “Strongly Agree” to the question using the Likert scale variables (5 categories
strongly disagree to strongly agree). The numerators represent the total number of responses for “Agree” or “Strongly Agree” and denominators represent the total number
of responses for each item in all 5 categories (strongly disagree to strongly agree). Generalized estimating equations models were used to test for associations of perceived
benefits and risks across the three scenarios while accounting for the clustering within survey respondents.
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TABLE 3 | Test interest by scenario.
Scenario response: Would you take this genomic screening test?
Test scenario Not likelya N (%) Likelyb N (%) OR (95% CI) p-value
Employer-based (wGTc) (N = 512) 153 (29.9) 359 (70.1) 1.99 (1.63, 2.43) <0.0001
Doctor’s office (N = 529) 243 (45.9) 286 (54.1) Reference
Commercially available (N = 506) 403 (79.6) 103 (20.4) 0.22 (0.17, 0.28) <0.0001
aResponses: Definitely not, Probably not, Might or might not.
bResponses: Probably yes, Definitely yes.
cwGT: voluntary workplace genomic testing.
confidentiality; (2) effect on health insurance; (3) information on
laws protecting privacy; and (4) job protection (see Table 4).
Logistic univariate regression models assessing associations
between demographics and positive response to taking wGT
are described in Table 5. Younger age (p = 0.005) and lower
education levels (p < 0.0001) were the only demographic
variables with a statistically significant association with an
expressed preference for wGT. Higher perceived benefits and
lower perceived risks of wGT (except for understanding of test
and work absence) were also associated with interest in wGT (see
Supplementary Table S2). Additionally, in the genomic testing
at doctor’s office scenario, a univariate logistic regression model
revealed statistically significant associations with test interest
for younger age (p < 0.0001), recent employment (<10 years)
at JAX (p = 0.01), and lower education levels (p = 0.0006)
(see Supplementary Table S3). Similar analysis for the DTC
testing scenario did not reveal any significant associations
(see Supplementary Table S4). Higher perceived benefits and
lower perceived risks of doctor’s office-based testing (except for
understanding of test and work absence) were also associated
with interest in testing in a health care setting. Respondents
who expressed lower perceived risks for understanding and work
TABLE 4 | Supporting respondents’ quotes for broad categories of factors








“Assurance that the results would only be available to
myself and a genetic counselor if I chose to disclose
them.”
“Genetic testing company would not be able to see
information about me. Only the information I choose to
put in my medical record would go, not my whole result
file.”
“Iron-clad guarantee that employer cannot recover
individual info.”




“Assurance that results do not increase healthcare cost
or coverage and remain confidential.”
Information on laws
protecting privacy
“Written details on privacy of information and laws
protecting this information.”
Job protection “Assurance of privacy and job protection.”
These broad categories of factors that might impact the decision-making for wGT
were selected inductively using individual respondent responses. wGT, voluntary
workplace genomic testing.
absence were less likely to express interest in taking the test at
the doctor’s office. Higher perceived benefits and lower perceived
risks of doctor’s office-based testing (except for understanding of
test and work absence) were also associated with interest in the
DTC testing scenario. Higher perceived benefits of early diagnosis
and timely medical intervention and lower perceived risk of data
used by outside group were associated with interest in the DTC
testing scenario.
Preferences Related to the Process of
wGT
Of the three access points for genomic testing, 42% of
respondents felt most comfortable with wGT. Regarding
information that respondents wanted to know prior to
participating in wGT, 79% selected information about
confidentiality of test results, 70% of respondents selected
existence of relevant laws and policies, and 64% of respondents
selected privacy protection. Other topics that respondents
expressed an interest in knowing more about included potential
implications of the test result (50%) and possible impact of
testing on their family (34%). Note that respondents could check
multiple topics.
Of interest, ninety two percent of respondents agreed or
strongly agreed that they preferred to view the test results with
a genetic counselor, but only 38% of respondents preferred to
discuss medical and family history with a genetic counselor
before pursuing wGT. Ninety-nine percent of respondents agreed
or strongly agreed they would like to receive a copy of their wGT
results. Eighty-nine percent of respondents agreed or strongly
agreed they would like to get a letter from a genetic counselor
to learn the impact of their wGT test result on their health and
potentially, their family’s health. With regard to preferences for
how to receive a wGT test result, 58% of respondents ranked
an in-person session with a genetic counselor as their top
choice. A telephone session with a genetic counselor was second
most popular choice (24%). A web-based session with a genetic
counselor (28%) and an email link to a secure web portal with
test results (25%) were the next most popular choices. A written
summary of wGT test results was the least popular option, with
more than a third (36%) selecting it as their fifth choice.
DISCUSSION
This preliminary study focused on developing a better
understanding of employee attitudes regarding voluntary
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TABLE 5 | Logistic univariate regression assessing predictors of interest in wGT.
Sociodemographic characteristics OR (95% CI)
Sex: (N = 475)a P = 0.49
Female Reference
Male 1.16 (0.77, 1.76)
Age: (N = 488) P = 0.005
18–35 2.43 (1.31, 4.51)
36–55 1.29 (0.73, 2.27)
56 and above Reference
Years at JAX: (N = 492) P = 0.20
Less than a year 1.83 (0.81, 4.15)
1–2 1.51 (0.71, 3.21)
3–5 0.94 (0.46, 1.90)
6–9 1.13 (0.49, 2.62)
10–19 0.84 (0.41, 1.72)
More than 20 years Reference
Education: (N = 493) P < 0.0001
Associate degree or less 3.37 (1.87, 6.06)
Bachelor’s degree 2.85 (1.67, 4.88)
Master’s degree 1.15 (0.64, 2.07)
Ph.D./MD Reference
Education: (N = 493) P < 0.0001
High school or GED 9.33 (2.08, 41.81)
Some college/associate degree 2.87 (1.57, 5.27)
Bachelor’s degree 2.85 (1.67, 4.88)
Master’s degree 1.16 (0.64, 2.07)
Professional school/doctoral degree Reference
Race: (N = 454)a P = 0.89
White 0.96 (0.51, 1.80)
Not white Reference
aPrefer not to answer excluded and counted as missing. Responses of unsure were
included in the Strongly Disagree/Disagree/Neither agree nor disagree category for
the analyses of perceived benefit and perceived risks.
workplace genetic testing (wGT). Respondents, all of whom were
employees of a large biomedical research institution focused on
genetic research, expressed a significant preference for wGT over
genetic testing for disease risk in the setting of a doctor’s office
or through engagement of a DTC genetic testing company. As
genetic testing gains public acceptance, and as its perceived utility
for preventive care increases, questions arise as to the best venue
for offering testing. This preference for workplace testing is
significant and suggests that despite continued privacy concerns,
non-clinical settings for genetic testing have likely gained
wider acceptance than before. This is an important shift since,
approximately 60% of non-elderly adults in the U.S. have medical
coverage through employer-sponsored health insurance2. Of
this group, 61% are covered by self-funded plans3, meaning
that the employer pays the cost of healthcare for those covered.
Preventive health programs, which may increasingly include





incorporated into employer wellness programs. The confluence
of financing, availability of genetic testing, and workforce
acceptance may result in future sustainable growth of wGT.
The current wGT market is not entirely focused on medically
actionable genetic testing as was described in the imaginary
scenarios in the survey. This fact limits the generalizability of the
findings to a particular subset of genomic testing that is currently
available to many employees. However, the authors chose to
focus on medically actionable findings in this study because such
results are likely to be of particular interest to consumers, and are
likely to raise concerns regarding discrimination if the results are
improperly used.
One potential concern regarding widespread implementation
of wGT is that many individuals may fear that their data
could be used to discriminate against them. For example,
many individuals fear discrimination by employers and insurers,
even if they are aware of the provisions of the federal
Genetic Information Non-discrimination Act (GINA) of 2008
that protects individuals from discrimination based on genetic
information for employment and health insurance purposes
(Green et al., 2015). Other concerns such as secondary use of
the aggregated wGT results, might also affect implementation
of wGT in wellness programs. For example, the unwanted or
inappropriate sharing of aggregated wGT results could result
in unintended consequences in the absence of sufficient privacy
and confidentiality protections. The informed consent for wGT
might not address such consequences. These concerns could limit
the acceptability of employer-initiated genetic testing accessed
at the workplace.
Twenty two percent of respondents had prior experience with
a genomic test and 42% had accessed ancestry testing. This
suggests a familiarity with genetic testing in this population.
However, the preference for wGT suggests that at least some
employees informed about genetic testing are not averse to
genetic testing at the workplace.
In this study, most respondents were interested in wGT likely
because of its perceived medical value which raises questions
about why testing in the doctor’s office scenario was not the
most popular choice.
It is possible that respondent’s perceptions of potential out
of pocket cost considerations may have influenced expressed
preferences for wGT over testing in a doctor’s office. Further,
respondents indicated that privacy and confidentiality risks were
least concerning for wGT. Participants may have felt that there
were fewer privacy and confidentiality risks related to wGT
because wGT test results are not likely to be automatically
placed in a medical record. The specific basis for the preferences
and assumptions about privacy and confidentiality risk are not
elucidated by this survey. If validated in other settings it will
be important to understand the basis of these observations. In
this survey, the difference between wGT and a doctor’s office in
terms of test interest was not trivial: 70 vs. 54%, with just 20%
preferring DTC genetic testing. This level of interest in wGT may
be unique to this study population and could be attributed to a
possible familiarity of JAX employees with genomic testing, given
the genetics research focus of the institution. It might also reflect
unusually high levels of trust in their employer, or a belief that
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JAX would be particularly well suited to offer wGT. The role
of employees’ trust in their employer in pursuing or declining
wGT needs to be further evaluated as it is reported that a higher
level of trust is associated with higher uptake of genetic testing
(Boddington, 2009; Roberts et al., 2018). However, trust in the
employer may not be the only factor since counterintuitively,
respondents employed at JAX for over 10 years seemed less
interested in wGT.
There was an apparent inverse relationship between
educational status and preference for wGT among individuals
who completed this survey. It is possible that those with
lower levels of education might have perceived a higher
potential for benefit from wGT, given that they might
lack access to genetic testing or might face higher out-of-
pocket costs compared with those with higher levels of
education. Conversely, those with lower educational status
may not have fully explored the risks of wGT. The basis
for this inverse relationship and its implications regarding
implementation of wGT are not elucidated in this study
but constitute a potentially important avenue of exploration
in future studies.
Respondents generally reported higher agreement with
statements about perceived test benefits than with statements
about perceived risks and concerns, although a subset of
respondents expressed concerns regarding privacy and
confidentiality and data use by outside groups. These findings
are in accord with the outcome of a previously published
employee survey that showed many employees are inclined to
pursue wGT provided their genetic data would be kept safe1.
These factors included easy and affordable access to the test
with strict privacy and data ownership, allowing test result
access only to the employee and their doctor. Some respondents
were unsure about their appraisal of perceived benefits and
risks or concerns regarding genomic testing in the three
hypothetical scenarios. Taken together, these findings suggest a
role for employee education in wellness programs considering
incorporation of wGT, to inform employees about the long-
term risks associated with wGT and to provide opportunities
for the employees to assess the potential for protections to
mitigate this risk.
High levels of perceived benefit or low levels of perceived
risk were associated with an increased interest in wGT.
However, it remains to be seen whether these findings
can predict actual future utilization of wGT, as a sizeable
number of respondents (20%) indicated that there were
factors that would make them more comfortable or confident
about pursuing wGT. These factors included guarantees about
privacy and confidentiality, and assurances that test results
would not be shared, and health insurance costs would
not be increased.
Prior studies on prostate cancer (Harris et al., 2009)
and colorectal cancer (Kinney et al., 2000) have shown
an inverse association between age and interest in genetic
testing. This study also demonstrated an inverse relationship
between age and interest in wGT. These observations may
be due to a general tendency for younger individuals to
be comfortable with adopting new technology because of
its increased visibility in current culture and healthcare
(Khan and Mittelman, 2018). Older individuals may also
prefer or be unable to prioritize genetic testing due to a
variety of competing health and retirement related issues
(Harding et al., 2017). Also, screening of older individuals
might or might not yield the same perceived or actual
benefits as wGT of younger individuals (Waltz et al.,
2018). Alternatively, it may reflect a lack of understanding
of existing genetic privacy and discrimination concerns
related to genomic testing in workplace settings (Hudson and
Pollitz, 2017; Clayton et al., 2018; Golinghorst and Prince,
2020).
There is little published data regarding employees’ preferences
for return of wGT results, including the potential role of
genetic counselors in wGT (Hall and Rich, 2000; Brandt-Rauf
et al., 2011; McDonald et al., 2020). The results of this study
suggest that a majority (55%) of those interested in wGT
would like to receive their results in a meeting with a genetic
counselor. A prior study on ELSI of wGT emphasized the
inclusion of genetic counseling as a minimum requirement for
implementing wGT (Brandt-Rauf and Brandt-Rauf, 2004). Thus,
our findings reinforce this recommendation as a preference in an
employee cohort.
Limitations and Future Directions
This study has several limitations. First, the study population
represents a convenience sample of employees from a single,
U.S. based biomedical research institution whose mission is
focused on genetics and genomics. Also, the study sample was
predominantly white (88%) and therefore does not reflect the
diversity of the general U.S. population. The generalizability
of these findings to other settings or populations may be
limited, risking over-interpretation of the results and, taken
together, emphasize the need for a larger study with a more
socio-demographically diverse, randomly selected sample
in different workplace settings especially those settings
where the mission of the workplace is not in biomedical
research. Second, the study used hypothetical scenarios
to simulate real-world situations in which genetic testing
for disease risk might be offered. Historically wGT has
been thought of in the context of testing as a condition of
employment—which is inherently discriminatory (Draper,
1999). In the current wGT mode, the employer offers
such testing as a part of a benefits package, often in the
context of workplace wellness programs, rather than as a
precondition for employment. In the context of wellness
programs, employees do not need to pay for the test. This
may have influenced some respondents’ choice of testing
scenarios. Additionally, unless actively shared with their
medical provider, wellness program-based wGT results
are not included in the employees’ medical records (see
Supplementary Table S5). Third, the response rate to the
survey was modest, raising the possibility of non-response
bias affecting the representativeness of participants’ views on
wGT. Assessing non-responders in a meaningful way was
beyond the scope of this research survey as the IRB would
not have permitted such assessment. Fourth, the study did not
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evaluate the perceived or real trust of employees in institutional
leadership, which might influence employees’ interest in pursuing
or declining wGT. Fifth, demographic factors such as marital
status or dependents and campus location across different states
were not analyzed in the study. While there are limitations
of this study, to the author’s knowledge these are the first
data of this kind available for hypothesis generation for future
experimental testing.
CONCLUSION
This study of wGT provides evidence that health-related genetic
testing in a workplace setting is likely acceptable by the workforce,
and that many employees may prefer wGT over receiving
testing from a physician or a DTC company. Additionally,
the study provides evidence suggesting that younger employees
may be more interested in wGT, and that lower educational
status does not adversely affect interest in wGT. This study
should be viewed as hypothesis generating for future studies that
explore ELSI implications of wGT in other workplace settings.
For example, this work should be replicated in multiple types
of participant populations, perhaps using different sampling
frames for ascertaining participants other than through the
workforce. As the uptake of wGT continues to increase,
additional studies using mixed methods approaches in different
employment and demographic settings will be needed to validate
the observations in this study in a real-world context to assess
the actual demand for wGT and to evaluate whether any
perceived or real interest in wGT can translate into better
health outcomes in diverse workforces. Such studies will also
need to assess: (1) the workplace culture for any potential
coercive conditions; and (2) diversity of both employees and
organization’s leadership on how this affects the dynamics of
wGT; (3) participants’ trust in their employer; and (4) the factors
that influence executive leadership’s decisions regarding offering
wGT to employees.
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